Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?-Reference-Cited by-同舟云学术

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?

Published:2020-07-21 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Bai Rilan,Chen Naifei,Liang Tingting,Li Lingyu,Lv Zheng,Lv Xiaomin,Cui Jiuwei

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference70 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin.,2018

2. Treatment options in patients with metastatic gastric cancer: current status and future perspectives;Bilici;World J Gastroenterol,2014

3. Comprehensive molecular characterization of gastric adenocarcinoma;Nature.,2014

4. Outlooks on Epstein-Barr virus associated gastric cancer;Naseem;Cancer Treat Rev,2018

5. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors;Zhang;Int J Clin Exp Pathol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer;Frontiers in Immunology;2024-05-22

2. Identification of Low Expression of GSN as a Key Prognosis Gene in Patients with Gastric Carcinoma;Russian Journal of Genetics;2024-02

3. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer;Laboratory Investigation;2024-01

4. Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis;Therapeutic Advances in Gastroenterology;2023-01

5. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment;Aging;2022-01-24